|
KMID : 1038620150330030217
|
|
Radiation Oncology Journal
2015 Volume.33 No. 3 p.217 ~ p.225
|
|
|
Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma
|
|
Lee Eon-Ju
Kim Tae-Gyu
Park Hee-Chul
Yu Jeong-Il
Lim Do-Hoon
Nam Hee-Rim
Lee Hye-Bin
Lee Joon-Hyeok
|
|
|
Abstract
|
|
|
Purpose: To investigate the outcomes of patients with spinal metastases from hepatocellular carcinoma (HCC), who were treated by stereotactic body radiotherapy (SBRT).
Materials and Methods: This retrospective study evaluated 23 patients who underwent SBRT from October 2008 to August 2012 for 36 spinal metastases from HCC. SBRT consisted of approximately 2 fractionation schedules, which were 18 to 40 Gy in 1 to 4 fractions for group A lesions (n = 15) and 50 Gy in 10 fractions for group B lesions (n = 21).
Results: The median follow-up period was 7 months (range, 2 to 16 months). Seven patients developed grade 1 or 2 gastrointestinal toxicity, and one developed grade 2 leucopenia. Compression fractures occurred in association with 25% of the lesions, with a median time to fracture of 2 months. Pain relief occurred in 92.3% and 68.4% of group A and B lesions, respectively. Radiologic response (complete and partial response) occurred in 80.0% and 61.9% of group A and B lesions, respectively. The estimated 1-year spinal-tumor progression-free survival rate was 78.5%. The median overall survival period and 1-year overall survival rate were 9 months (range, 2 to 16 months) and 25.7%, respectively.
Conclusion: SBRT for spinal metastases from HCC is well tolerated and effective at providing pain relief and radiologic response. Because compression fractures develop at a high rate following SBRT for spinal metastases from primary HCC, careful follow up of the patient is required.
|
|
|
KEYWORD
|
|
|
Stereotactic body radiotherapy, Spinal metastases, Hepatocellular carcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|